The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modeling study

HIGHLIGHTS

• who: Allison Portnoy et al. from the Medical School, UNITED STATES University of Hong Kong, Hong Kong SAR, China, Department of Global Health and Population, Harvard have published the paper: The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study, in the Journal: (JOURNAL) of January/24,/2023
• what: The results of this analysis demonstrate that, when available, TB vaccines could be cost-effective in a majority of LMICs, particularly from the societal perspective, and in essentially all high-burden countries.
• how: The authors developed . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.